All News

Across both pretreated cervical cancer and PROC populations, no new safety signals and low rates of treatment discontinuation were observed with DB-1311/BNT324.

Making pancreatic cancer an immunotherapy-receptive disease requires identifying select patient subgroups who may benefit.

Combining ctDNA and modern imaging with novel therapeutics may help determine subsets of patients who are eligible to receive reduced treatment courses.

Orca-T may facilitate faster immune reconstitution in patients who undergo allogeneic transplant, according to Wendy Stock, MD.

Ting Bao, MD, MS, suggested chemotherapy-induced neuropathy could be mitigated through acupuncture, although phase 3 clinical trial results are pending.

A prospective evaluation shows that using large language models within an oncology-specific knowledge graph may help close oncology's enrollment crisis.

An analysis conducted by Starr and associates showed that patients with high disease burden in the liver did not experience liver failure with PRRT.

In the phase 3 NRG-GY019 trial, while letrozole monotherapy was more tolerable, it did not achieve noninferiority compared with chemotherapy and letrozole.

Activity stemming from abemaciclib plus letrozole was most pronounced in chemotherapy-naive patients with advanced endometrioid endometrial carcinoma.

Updated results from the phase 2 RAMP 201 trial show that avutometinib plus defactinib provides durable efficacy and a manageable safety profile in patients with LGSOC.

The SISTER trial was the first national randomized trial to demonstrate significantly improved outcomes for black women with endometrial cancer.

Microsatellite instability-high status may make patients suitable candidates to receive agents like pembrolizumab, according to Steven Bialick, DO.

A retrospective review showed an ORR of 42.9% in radiated fields vs 35.7% in non-radiated fields among patients with cervical cancer who received tisotumab vedotin.

Phase 1/2 data may warrant further investigation of belantamab mafodotin plus lenalidomide/dexamethasone in randomized controlled studies.

Final overall survival data from the phase 3 ROSELLA trial showed that the addition of relacorilant to nab-paclitaxel extended median survival to 16.0 months in patients with platinum-resistant ovarian cancer.

Data from the EMPOWER-Lung 1 study reinforce the value of long-term immune checkpoint inhibition in PD-L1–high non–small cell lung cancer.

Alexander Z. Wei, MD, identified key abstracts in bladder and kidney cancer to optimize treatment in select patient groups.

The FDA cited that the data provided for RP1 were insufficient and did not provide substantial evidence of effectiveness for this population.

CT-P71 is being assessed in patients with locally advanced or metastatic urothelial carcinoma.

The FDA has set a Prescription Drug User Fee Act date of September 11, 2026, for TLX101-Px for patients with brain cancer.

Elizabeth Mittendorf, MD, discussed how the Clarity Breast AI tool utilizes mammography to predict 5-year breast cancer risk.

Integrative analysis reveals that targeting uPAR with CAR T cells produces durable regressions as well as systemic metastasis clearance.

The FDA has removed the partial clinical hold on the phase 2 LINNET study of lorigerlimab for patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer.

The FDA has also approved the BD Onclarity HPV Assay for the screening of cervical cancer, with support from the SHIP trial evaluating at-home cervical cancer screening.

Treatment with Rhenium-186 Obisbemeda for pediatric malignant gliomas and ependymomas is being assessed in the ReSPECT-PBC trial.

Alexander Z. Wei, MD, highlighted key clinical trials presented at ASCO GU and initiated at Columbia University to “move the needle” in bladder cancer.

JNJ-1900 may avoid the main limitations observed with other radiosensitizers and radioprotectors, according to Benjamin Cooper, MD.

Mina Fam, MD, discussed his use of MRI and genomic testing to inform his use of HIFU focal therapies vs more radical alternatives.

A large community-based chart review demonstrates robust real-world responses with tafasitamab/lenalidomide across a racially diverse US population.

Jamin C. Morrison, MD, discussed the shift toward personalized cancer vaccines in melanoma.